Cantargia AB | Income Statement

Fiscal year is January-December. All values SEK Thousands.
2013
2014
2015
2016
2017
Cost of Goods Sold (COGS) incl. D&A
2,204.60
-
-
-
-
Gross Income
2,204.60
-
-
-
-
SG&A Expense
-
8,115.60
16,808.00
47,399.00
59,800.00
EBIT
7,977.70
8,115.60
16,808.00
-
59,800.00
Unusual Expense
-
-
128.00
66.00
13.00
Non Operating Income/Expense
-
269.10
275.00
160.00
536.00
Pretax Income
7,945.90
8,370.20
17,190.00
47,490.00
60,253.00
Consolidated Net Income
7,945.90
8,370.20
17,190.00
47,490.00
60,253.00
Net Income
7,945.90
8,370.20
17,190.00
47,490.00
60,253.00
Net Income After Extraordinaries
7,945.90
8,370.20
17,190.00
47,490.00
60,253.00
Net Income Available to Common
7,945.90
8,370.20
17,190.00
47,490.00
60,253.00
EPS (Basic)
43.73
-
1.20
2.57
1.86
Basic Shares Outstanding
14,196.10
14,196.10
14,313.70
18,472.60
32,384.00
EPS (Diluted)
0.56
0.59
1.20
2.57
1.86
Diluted Shares Outstanding
14,196.10
14,196.10
14,313.70
18,472.60
32,384.00
EBITDA
-
8,115.60
-
47,399.00
59,800.00
Other Operating Expense
5,773.10
-
0.00
-
-
Non-Operating Interest Income
31.70
14.40
21.00
3.00
70.00

About Cantargia AB

View Profile
Address
Medicon Village
Lund SN 223 81
Sweden
Employees -
Website http://www.cantargia.com
Updated 09/14/2018
Cantargia AB is a holding company, which engages in the development of antibody-based cancer treatment. It focuses on the development of CAN04 for the treatment of non-small cell lung cancer and pancreatic cancer. The company was founded by Thoas Michael Fioretos, Kjell Torsten Sjostrom, and Marcus Jaras on October 26, 2009 and is headquartered in Lund, Sweden.